See more : Savera Industries Limited (SAVERA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Exicure, Inc. (XCUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Exicure, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Oramed Pharmaceuticals Inc. (ORMP.TA) Income Statement Analysis – Financial Results
- Adams Plc (ADA.L) Income Statement Analysis – Financial Results
- MAAGH ADVERTISING AND MARKETIN (MAAGHADV.BO) Income Statement Analysis – Financial Results
- Daiwa House Industry Co., Ltd. (1925.T) Income Statement Analysis – Financial Results
- Sitio Royalties Corp. (STR-WT) Income Statement Analysis – Financial Results
Exicure, Inc. (XCUR)
About Exicure, Inc.
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 28.83M | -483.00K | 16.61M | 1.30M | 118.00K | 9.72M | 1.04M | 2.39M |
| Cost of Revenue | 920.00K | 1.86M | 1.78M | 32.09M | 19.34M | 14.12M | 13.08M | 13.66M | 10.12M |
| Gross Profit | -1.42M | 26.97M | -2.26M | -15.48M | -18.04M | -14.00M | -3.36M | -12.62M | -7.74M |
| Gross Profit Ratio | 0.00% | 93.56% | 468.32% | -93.19% | -1,392.28% | -11,865.25% | -34.58% | -1,218.44% | -323.95% |
| Research & Development | 1.42M | 19.77M | 48.98M | 32.09M | 19.34M | 14.12M | 13.08M | 13.66M | 10.12M |
| General & Administrative | 12.65M | 10.89M | 13.09M | 9.96M | 8.57M | 7.82M | 7.05M | 3.54M | 5.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -133.00K |
| SG&A | 12.65M | 10.89M | 13.09M | 9.96M | 8.57M | 7.82M | 7.05M | 3.54M | 5.28M |
| Other Expenses | 0.00 | -40.00K | -11.00K | 322.00K | 379.00K | -249.00K | 191.00K | -55.00K | 0.00 |
| Operating Expenses | 14.08M | 30.66M | 62.07M | 42.05M | 27.91M | 21.94M | 20.13M | 17.20M | 15.40M |
| Cost & Expenses | 15.00M | 30.66M | 62.07M | 42.05M | 27.91M | 21.94M | 20.13M | 17.20M | 15.53M |
| Interest Income | 32.00K | 15.00K | 141.00K | 972.00K | 178.00K | 4.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 595.00K | 1.69M | 573.00K | 786.00K | 672.00K | 795.00K | 724.00K | 0.00 |
| Depreciation & Amortization | 1.38M | 1.86M | 1.78M | 1.45M | 724.00K | 358.00K | 232.00K | 180.00K | 133.00K |
| EBITDA | -15.54M | 78.00K | -60.63M | -22.65M | -24.79M | -21.38M | -9.98M | -16.04M | -13.02M |
| EBITDA Ratio | 0.00% | -1.93% | 12,554.87% | -136.61% | -1,954.94% | -18,394.92% | -102.73% | -1,547.97% | -544.85% |
| Operating Income | -15.00M | -1.83M | -62.55M | -25.44M | -26.62M | -21.82M | -10.41M | -16.16M | -13.14M |
| Operating Income Ratio | 0.00% | -6.35% | 12,950.10% | -153.11% | -2,053.78% | -18,490.68% | -107.08% | -1,560.04% | -550.42% |
| Total Other Income/Expenses | -1.92M | -542.00K | -1.55M | 768.00K | 314.00K | -594.00K | -604.00K | -779.00K | -7.00K |
| Income Before Tax | -16.91M | -2.37M | -64.10M | -24.67M | -26.30M | -22.41M | -11.01M | -16.94M | -13.15M |
| Income Before Tax Ratio | 0.00% | -8.23% | 13,271.64% | -148.49% | -2,029.55% | -18,994.07% | -113.29% | -1,635.23% | -550.71% |
| Income Tax Expense | 0.00 | 209.00K | 1.68M | 895.00K | 1.17M | 423.00K | 986.00K | 669.00K | 0.00 |
| Net Income | -16.91M | -2.58M | -64.10M | -24.67M | -26.30M | -22.41M | -11.01M | -16.94M | -13.15M |
| Net Income Ratio | 0.00% | -8.96% | 13,271.64% | -148.49% | -2,029.55% | -18,994.07% | -113.29% | -1,635.23% | -550.71% |
| EPS | -2.11 | -0.56 | -21.70 | -8.49 | -13.68 | -16.32 | -8.37 | -12.93 | -10.04 |
| EPS Diluted | -2.11 | -0.56 | -21.70 | -8.49 | -13.68 | -16.32 | -8.37 | -12.88 | -10.04 |
| Weighted Avg Shares Out | 8.01M | 4.62M | 2.95M | 2.91M | 1.92M | 1.37M | 1.32M | 1.31M | 1.31M |
| Weighted Avg Shares Out (Dil) | 8.01M | 4.62M | 2.95M | 2.91M | 1.92M | 1.37M | 1.32M | 1.32M | 1.31M |
What to Know About Buying Penny Stocks on May 20th
Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 20th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.
Check These 3 Hot Penny Stocks Out For Your List This Week
Here are three penny stocks to add to your watchlist this week The post Check These 3 Hot Penny Stocks Out For Your List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Exicure Shares Plunge After Q4 Results Included A Going Concern Risk
Exicure Inc (NASDAQ: XCUR) has reported year-end cash, cash equivalents, and short-term investments of $48.3 million that will fund its current operations into Q4 of 2022. The Company said that it expects to continue to generate operating losses and negative operating cash.
Good Trending Penny Stocks to Buy Now? Check These 3 Out
Check these trending penny stocks out for your watchlist The post Good Trending Penny Stocks to Buy Now? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
4 Top Penny Stocks To Buy For Under $1 This Week
Penny stocks to watch under $1 this week. The post 4 Top Penny Stocks To Buy For Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Popular Reddit Penny Stocks to Watch In February 2022
Check these Reddit penny stocks out for your watchlist right now The post Popular Reddit Penny Stocks to Watch In February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
5 Top Penny Stocks To Buy Under $1 On Webull According To Reddit
Penny stocks under $1 The post 5 Top Penny Stocks To Buy Under $1 On Webull According To Reddit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Exicure Stock (XCUR) Price Surges Today: Details You Should Know
The stock price of Exicure Inc (NASDAQ: XCUR) increased by over 30% pre-market today. These are some details you should know.
Exicure Stock (XCUR): Why The Price Surged Today
The stock price of Exicure Inc (NASDAQ: XCUR) increased by over 60% pre-market today. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports